DRRX - DURECT Operating income before deduction of amortization

Graphic logo of durect.com (DRRX)

DURECT Corporation (DRRX) management effectively advances R&D by leveraging external investments. The absolute operating profit metric reflects cash flow dynamics, where the mark characterizes this parameter. DURECT Corporation is diversifying its pipeline by developing therapies for the skin and liver. Epigenetics patents and strict FDA oversight create significant barriers to entry for new market participants.

DRRX (DURECT) Operating profit EBITDA history from 07/04/2022 to 11/12/2026

DURECT (DRRX) - metric breakdowns and financial figures

- stock price and consensus target price:
Price Chart DURECT Corp|DRRX - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization DURECT|DRRX - Real Price to Acquire Entire Company
- balance sheet equity data:
Net Assets per Single Share DURECT|DRRX - Book Capitalization|Market-to-Book Ratio durect.com|DRRX - Aggregate Company Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio DURECT Corporation|DRRX - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio DURECT Corp|DRRX - Company Total Debt|Debts to Book Capitalization DURECT|DRRX - Company Long-Term Debt|Company Short-Term Loans and Borrowings DURECT|Immediate Liquidity durect.com
- net income and valuation multiples indicators:
DRRX - Net Profit|Future Profit DURECT Corporation|DRRX - Price to Earnings Ratio|Market Cap to Future Earnings Ratio DURECT Corp|DRRX - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation DURECT|DRRX - Operating profit EBITDA|Net earnings per share for the last 12 months DURECT|DRRX - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months durect.com|DRRX - Earnings per share growth in current year|Expected earnings per share trend next year DURECT Corporation
Fundamental company valuation:DRRX (DURECT Corporation)
Brand item of DURECT Corporation

The strong pricing power of DURECT Corporation (DRRX) in the hepatitis therapy segment makes the EBITDA chart a key tool for assessing the monetization of unique epigenetic control of gene expression. This metric isolates net cash flow from the impact of non-cash write-downs, allowing investors to differentiate real business growth from speculative stock price inflation through the analysis of this chart.

Competitors of DURECT Corporation (DRRX)

Arrowhead Corp - Profit before payment of interest, taxes and amortization|Mirum Pharmaceuticals - Operating profit EBITDA|Operating income before deduction of amortization Dynavax Technologies Corp DVAX|ABUS (Arbutus Biopharma Corporation) - Operating profit before deduction of amortization|IVA (Inventiva SA) - Profit before payment of interest, taxes and amortization|GYRE (Gyre Corp) - Operating profit EBITDA|Profit before interest, taxes and amortization Assembly Corp ASMB|Profit before payment of interest, taxes and amortization Galectin Therapeutics (GALT)|GNFT (genfit.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA ALGS (Aligos Therapeutics, Inc.)|BIVI: Operating profit before amortization|GLMD: Operating profit before deduction of amortization|NDRA - Operating profit EBITDA|hepionpharma.com (HEPA) - Profit before payment of interest, taxes and amortization